Moving toward the ideal insulin for insulin pumps

Expert Review of Medical Devices

Volumn 13, Issue 1, 2016, Pages 57-69

  Cengiz, Eda ^a   Bode, Bruce ^b   Van Name, Michelle ^a   Tamborlane, William V ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ATLANTA DIABETES ASSOCIATES   (United States)

Author keywords

CGM; closed loop delivery system; CSII; faster acting insulin aspart; hyaluronidase; inhaled insulin; pump; site warming devices; ultra fast acting insulin analogs

Indexed keywords

ARTIFICIAL ORGANS; CLOSED LOOP CONTROL SYSTEMS; PUMPS; QUALITY CONTROL;

CSII; DELIVERY SYSTEMS; FASTER-ACTING INSULIN ASPART; HYALURONIDASE; SITE-WARMING DEVICES; ULTRA-FAST;

INSULIN;

INSULIN; INSULIN DERIVATIVE; INSULIN LISPRO; SHORT ACTING INSULIN;

AREA UNDER THE CURVE; BLOOD GLUCOSE MONITORING; DIABETES MELLITUS; DRUG ABSORPTION; DRUG MECHANISM; DRUG RESPONSE; GLYCEMIC CONTROL; HUMAN; INFUSION PUMP; INSULIN PUMP; INSULIN TREATMENT; LIPODYSTROPHY; MEDICAL TECHNOLOGY; MICRONEEDLE; PUBERTY; QUALITY OF LIFE; REVIEW; TIME TO MAXIMUM PLASMA CONCENTRATION; TRANSDERMAL PATCH; ABSORPTION; AMINO ACID SEQUENCE; CHEMISTRY; DRUG EFFECTS; INSULIN INFUSION; MOLECULAR GENETICS;

ABSORPTION, PHYSIOLOGICAL; AMINO ACID SEQUENCE; HUMANS; INSULIN; INSULIN INFUSION SYSTEMS; INSULIN, SHORT-ACTING; MOLECULAR SEQUENCE DATA;

EID: 84956660091     PISSN: 17434440     EISSN: 17452422     Source Type: Journal    
DOI: 10.1586/17434440.2016.1109442     Document Type: Review

References (105)

1. Bryant W, Greenfield JR, Chisholm DJ, et al. Diabetes guidelines: easier to preach than to practise? Med J Aust. 2006;185:305-309.
2. Wood JR, Miller KM, Maahs DM, et al. Most youth with type 1 diabetes in the T1D exchange clinic registry do not meet American Diabetes Association or International Society for Pediatric and Adolescent Diabetes clinical guidelines. Diabet Care. 2013;36:2035-2037.
3. Pickup JC. Insulin-pump therapy for type 1 diabetes mellitus. N Engl J Med. 2012;366:1616-1624.
4. Tamborlane WV, Sherwin RS, Genel M, et al. Reduction to normal of plasma glucose in juvenile diabetes by subcutaneous administration of insulin with a portable infusion pump. N Engl J Med. 1979;300:573-578.
5. Misso ML, Egberts KJ, Page M, et al. Continuous subcutaneous insulin infusion (CSII) versus multiple insulin injections for type 1 diabetes mellitus. Cochrane Database Syst Rev. 2010;1:CD005103.
6. Cengiz E, Sherr JL, Weinzimer SA, et al. New-generation diabetes management: glucose sensor-augmented insulin pump therapy. Expert Rev Med Devices. 2011;8:449-458.
7. Sheldon B, Russell-Jones D, Wright J. Insulin analogues: an example of applied medical science. Diabet Obes Metab. 2009;11:5-19.
8. Humalog (insulin lispro injection), for subcutaneous or intravenous use [prescribing information]. Indianapolis (IN): Lilly USA, LLC; 2015.
9. NovoLog (insulin aspart [rDNA origin] injection) solution for subcutaneous use [prescribing information]. Princeton (NJ): Novo Nordisk Inc; 2009.
10. APIDRA (insulin glulisine [rDNA origin] injection) [prescribing information]. Bridgewater (NJ): Sanofi-Aventis US LLC; 2014.
11. Zinman B, Tildesley H, Chiasson JL, et al. Insulin lispro in CSII: results of a double-blind crossover study. Diabetes. 1997;46:440-443.
12. Feinglos MN, Thacker CH, English J, et al. Modification of postprandial hyperglycemia with insulin lispro improves glucose control in patients with type 2 diabetes. Diabet Care. 1997;20:1539-1542.
13. Kaiserman K, Rodriguez H, Stephenson A, et al. Continuous subcutaneous infusion of insulin lispro in children and adolescents with type 1 diabetes mellitus. Endocr Pract. 2012;18:418-424.
14. Bode BW, Strange P. Efficacy, safety, and pump compatibility of insulin aspart used in continuous subcutaneous insulin infusion therapy in patients with type 1 diabetes. Diabet Care. 2001;24:69-72.
15. Rosenfalck AM, Thorsby P, Kjems L, et al. Improved postprandial glycaemic control with insulin aspart in type 2 diabetic patients treated with insulin. Acta Diabetol. 2000;37:41-46.
16. Weinzimer SA, Ternand C, Howard C, et al. A randomized trial comparing continuous subcutaneous insulin infusion of insulin aspart versus insulin lispro in children and adolescents with type 1 diabetes. Diabet Care. 2008;31:210-215.
17. Hoogma RP, Schumicki D. Safety of insulin glulisine when given by continuous subcutaneous infusion using an external pump in patients with type 1 diabetes. Horm Metab Res. 2006;38:429-433.
18. Edelman SV, Bode BW, Bailey TS, et al. Insulin pump therapy in patients with type 2 diabetes safely improved glycemic control using a simple insulin dosing regimen. Diabet Technol Ther. 2010;12:627-633.
19. DeFelippis MR, Bell MA, Heyob JA, et al. In vitro stability of insulin lispro in continuous subcutaneous insulin infusion. Diabet Technol Ther. 2006;8:358-368.
20. Senstius J, Poulsen C, Hvass A. Comparison of in vitro stability for insulin aspart and insulin glulisine during simulated use in insulin pumps. Diabet Technol Ther. 2007;9:517-521.
21. Kerr D, Morton J, Whately-Smith C, et al. Laboratory-based non-clinical comparison of occlusion rates using three rapid-acting insulin analogs in continuous subcutaneous insulin infusion catheters using low flow rates. J Diabetes Sci Technol. 2008;2:450-455.
22. Poulsen C, Langkjaer L, Worsoe C. Precipitation of insulin aspart and insulin glulisine products used for continuous subcutaneous insulin infusion. Diabet Technol Ther. 2007;9:26-35.
23. Senesh G, Bushi D, Neta A, et al. Compatibility of insulin lispro, aspart, and glulisine with the Solo MicroPump, a novel miniature insulin pump. J Diabetes Sci Technol. 2010;4:104-110.
24. Heinemann L, Krinelke L. Insulin infusion set: the Achilles heel of continuous subcutaneous insulin infusion. J Diabetes Sci Technol. 2012;6:954-964.
25. Sampson Perrin AJ, Guzzetta RC, Miller KM, et al. A web-based study of the relationship of duration of insulin pump infusion set use and fasting blood glucose level in adults with type 1 diabetes. Diabet Technol Ther. 2015;17:307-310.
26. Thethi TK, Rao A, Kawji H, et al. Consequences of delayed pump infusion line change in patients with type 1 diabetes mellitus treated with continuous subcutaneous insulin infusion. J Diabet Complications. 2010;24:73-78.
27. van Bon AC, Bode BW, Sert-Langeron C, et al. Insulin glulisine compared to insulin aspart and to insulin lispro administered by continuous subcutaneous insulin infusion in patients with type 1 diabetes: a randomized controlled trial. Diabet Technol Ther. 2011;13:607-614.
28. Naik S, Kerr D, Begley J, et al. Influence of local skin temperature and choice of insulin analog on catheter occlusion rates during continuous insulin infusion: an exploratory study. Diabet Technol Ther. 2012;14:1018-1022.
29. Bode B, Weinstein R, Bell D, et al. Comparison of insulin aspart with buffered regular insulin and insulin lispro in continuous subcutaneous insulin infusion: a randomized study in type 1 diabetes. Diabet Care. 2002;25:439-444.
30. Bartolo PD, Pellicano F, Scaramuzza A, et al. Better postprandial glucose stability during continuous subcutaneous infusion with insulin aspart compared with insulin lispro in patients with type 1 diabetes. Diabet Technol Ther. 2008;10:495-498.
31. Tamborlane WV, Renard E, Wadwa RP, et al. Glycemic control after 6 days of insulin pump reservoir use in type 1 diabetes: results of double-blind and open-label cross-over trials of insulin lispro and insulin aspart. J Diabet. 2014;7:270-278.
32. Arnolds S, Kuglin B, Kapitza C, et al. How pharmacokinetic and pharmacodynamic principles pave the way for optimal basal insulin therapy in type 2 diabetes. Int J Clin Pract. 2010;64:1415-1424.
33. Evans M, Schumm-Draeger PM, Vora J, et al. A review of modern insulin analogue pharmacokinetic and pharmacodynamic profiles in type 2 diabetes: improvements and limitations. Diabet Obes Metab. 2011;13:677-684.
34. Jain L, Parks MH, Sahajwalla C. Determination of time to onset and rate of action of insulin products: importance and new approaches. J Pharm Sci. 2013;102:271-279.
35. Heinemann L, Weyer C, Rauhaus M, et al. Variability of the metabolic effect of soluble insulin and the rapid-acting insulin analog insulin aspart. Diabet Care. 1998;21:1910-1914.
36. Heinemann L, Klappoth W, Rave K, et al. Intra-individual variability of the metabolic effect of inhaled insulin together with an absorption enhancer. Diabet Care. 2000;23:1343-1347.
37. Swan KL, Weinzimer SA, Dziura JD, et al. Effect of puberty on the pharmacodynamic and pharmacokinetic properties of insulin pump therapy in youth with type 1 diabetes. Diabet Care. 2008;31:44-46.
38. Heinemann L, Heise T, Jorgensen LN, et al. Action profile of the rapid acting insulin analogue: human insulin B28Asp. Diabet Med. 1993;10:535-539.
39. Heinemann L, Heise T, Wahl LC, et al. Prandial glycaemia after a carbohydrate-rich meal in type I diabetic patients: using the rapid acting insulin analogue [Lys (B28), Pro(B29)] human insulin. Diabet Med. 1996;13:625-629.
40. Howey DC, Bowsher RR, Brunelle RL, et al. [Lys(B28), Pro(B29)]-human insulin. A rapidly absorbed analogue of human insulin. Diabetes. 1994;43:396-402.
41. Ter Braak EW, Woodworth JR, Bianchi R, et al. Injection site effects on the pharmacokinetics and glucodynamics of insulin lispro and regular insulin. Diabet Care. 1996;19:1437-1440.
42. Heise T, Weyer C, Serwas A, et al. Time-action profiles of novel premixed preparations of insulin lispro and NPL insulin. Diabet Care. 1998;21:800-803.
43. Mudaliar SR, Lindberg FA, Joyce M, et al. Insulin aspart (B28 asp-insulin): a fast-acting analog of human insulin: absorption kinetics and action profile compared with regular human insulin in healthy nondiabetic subjects. Diabet Care. 1999;22:1501-1506.
44. Rave KM, Nosek L, de la Pena A, et al. Dose response of inhaled dry-powder insulin and dose equivalence to subcutaneous insulin lispro. Diabet Care. 2005;28:2400-2405.
45. Heise T, Nosek L, Spitzer H, et al. Insulin glulisine: a faster onset of action compared with insulin lispro. Diabet Obes Metab. 2007;9:746-753.
46. Steiner S, Hompesch M, Pohl R, et al. A novel insulin formulation with a more rapid onset of action. Diabetologia. 2008;51:1602-1606.
47. Becker RH, Frick AD, Nosek L, et al. Dose-response relationship of insulin glulisine in subjects with type 1 diabetes. Diabet Care. 2007;30:2506-2507.
48. Vaughn DE, Yocum RC, Muchmore DB, et al. Accelerated pharmacokinetics and glucodynamics of prandial insulins injected with recombinant human hyaluronidase. Diabet Technol Ther. 2009;11:345-352.
49. Cengiz E, Tamborlane WV, Martin-Fredericksen M, et al. Early pharmacokinetic and pharmacodynamic effects of mixing lispro with glargine insulin: results of glucose clamp studies in youth with type 1 diabetes. Diabet Care. 2010;33:1009-1012.
50. Cengiz E, Weinzimer SA, Sherr JL, et al. Acceleration of insulin pharmacodynamic profile by a novel insulin infusion site warming device. Pediatr Diabet. 2013;14:168-173.
51. Cengiz E, Weinzimer SA, Sherr JL, et al. Faster in and faster out: accelerating insulin absorption and action by insulin infusion site warming. Diabet Technol Ther. 2014;16:20-25.
52. Pfutzner A, Hermanns N, Funke K, et al. The Barmer study: impact of standardized warming of the injection site to enhance insulin absorption and reduce prandial insulin requirements and hypoglycemia in obese patients with diabetes mellitus. Curr Med Res Opin. 2014;30:753-760.
53. Swan KL, Dziura JD, Steil GM, et al. Effect of age of infusion site and type of rapid-acting analog on pharmacodynamic parameters of insulin boluses in youth with type 1 diabetes receiving insulin pump therapy. Diabet Care. 2009;32:240-244.
54. Vaughn DE, Muchmore DB. Use of recombinant human hyaluronidase to accelerate rapid insulin analogue absorption: experience with subcutaneous injection and continuous infusion. Endocr Pract. 2011;17:914-921.
55. Cengiz E, Swan KL, Tamborlane WV, et al. The alteration of aspart insulin pharmacodynamics when mixed with detemir insulin. Diabet Care. 2012;35:690-692.
56. Tucker ME. New insulin pump prompts "first artificial pancreas" headlines. Medscape Medical News [Internet]. 2015 [updated 2015 Jan 23; cited 2015 Apr 9]. Available from: http://www.medscape.com/viewarticle/838627.
57. Sarno MJ, Bell J, Edelman SV. Pharmacokinetics and glucodynamics of rapid-, short-, and intermediate-acting insulins: comparison of jet injection to needle syringe. Diabet Technol Ther. 2002;4:863-866.
58. Engwerda EE, Abbink EJ, Tack CJ, et al. Improved pharmacokinetic and pharmacodynamic profile of rapid-acting insulin using needle-free jet injection technology. Diabet Care. 2011;34:1804-1808.
59. Morrow L, Canney L, Pichotta P, et al. Concentrated insulin BIOD-531 is associated with accelerated onset of action compared to Humulin® R U-500 and Humalog® Mix75/25™ and a basal duration profile [abstract]. Diabetes [Internet]. 2014 [cited 2014 Jan 13];63(Suppl 1). Available from: http://app.coreapps.com/tristar-ada14/abstract/e3048dedfd3d5fbcc516bc8638378046.
60. Morrow L, Muchmore DB, Hompesch M, et al. Comparative pharmacokinetics and insulin action for three rapid-acting insulin analogs injected subcutaneously with and without hyaluronidase. Diabet Care. 2013;36:273-275.
61. Heise T, Hovelmann U, Brondsted L, et al. Faster-acting insulin aspart: earlier onset of appearance and greater early pharmacokinetic and pharmacodynamic effects than insulin aspart. Diabet Obes Metab. 2015;17:682-688.
62. Raz I, Weiss R, Yegorchikov Y, et al. Effect of a local heating device on insulin and glucose pharmacokinetic profiles in an open-label, randomized, two-period, one-way crossover study in patients with type 1 diabetes using continuous subcutaneous insulin infusion. Clin Ther. 2009;31:980-987.
63. Rave K, Heise T, Heinemann L, et al. Inhaled Technosphere insulin in comparison to subcutaneous regular human insulin: time action profile and variability in subjects with type 2 diabetes. J Diabetes Sci Technol. 2008;2:205-212.
64. Landau Z, Klonoff D, Nayberg I, et al. Improved pharmacokinetic and pharmacodynamic profiles of insulin analogues using InsuPatch, a local heating device. Diabet Metab Res Rev. 2014;30:686-692.
65. Pettis RJ, Ginsberg B, Hirsch L, et al. Intradermal microneedle delivery of insulin lispro achieves faster insulin absorption and insulin action than subcutaneous injection. Diabet Technol Ther. 2011;13:435-442.
66. Andersen G, Alluis B, Meiffren G, et al. The ultra-rapid BioChaperone insulin lispro (BC LIS) shows a faster onset of action and stronger early metabolic effect than insulin lispro (LIS) [abstract]. Diabetes [Internet]. 2014 [cited 2015 Jan 12];63(suppl1). Available from: http://ada.scientificposters.com/epsAbstractADA.cfm?id=1.
67. Food and Drug Administration. Inactive ingredient search for approved drug products [Internet]; [cited 2014 Nov]. Available from: http://www.accessdata.fda.gov/scripts/cder/iig/getiigWEB.cfm.
68. Heise T, Haahr H, Jensen L, et al. Faster-acting insulin aspart improves postprandial glycemia vs insulin aspart in patients with type 1 diabetes mellitus (T1DM) [abstract]. Diabetes. 2014;63(Suppl 1):A34.
69. Bode B, Hyveled L, Tamer SC, et al. Improved postprandial glycemic control with faster-acting insulin aspart in patients with type 1 diabetes using CSII. Presented at the 75th Scientific Sessions American Diabetes Association; 2015June; Boston, MA. Abstract: 994P.
70. Krasner A, Pohl R, Simms P, et al. A review of a family of ultra-rapid-acting insulins: formulation development. J Diabetes Sci Technol. 2012;6:786-796.
71. Heinemann L, Hompesch M, Flacke F, et al. Reduction of postprandial glycemic excursions in patients with type 1 diabetes: a novel human insulin formulation versus a rapid-acting insulin analog and regular human insulin. J Diabetes Sci Technol. 2011;5:681-686.
72. Heinemann L, Nosek L, Flacke F, et al. U-100, pH-Neutral formulation of VIAject((R)): faster onset of action than insulin lispro in patients with type 1 diabetes. Diabet Obes Metab. 2012;14:222-227.
73. Soula O, Soula R, Alluis B, et al. Pharmacodynamic and pharmacokinetic profiles of Adoica's fast-acting biochaperone human insulin formulation [abstract]. Diabetes [Internet]. 2011 [cited 2014 Nov 20];60(Suppl 1). Available from: http://professional.diabetes.org/Abstracts-Display.aspx?TYP=1&CID=87456.
74. Boss AH, Petrucci R, Lorber D. Coverage of prandial insulin requirements by means of an ultra-rapid-acting inhaled insulin. J Diabetes Sci Technol. 2012;6:773-779.
75. Zisser H, Jovanovic L, Markova K, et al. Technosphere insulin effectively controls postprandial glycemia in patients with type 2 diabetes mellitus. Diabet Technol Ther. 2012;14:997-1001.
76. Tack CJ, Christov V, De Galan BE, et al. Randomized forced titration to different doses of technosphere insulin demonstrates reduction in postprandial glucose excursions and hemoglobin A1c in patients with type 2 diabetes. J Diabetes Sci Technol. 2008;2:47-57.
77. Bergenstal R, Kapsner P, Rendell M, et al. Comparative efficacy and safety of AFRESA and rapid acting analog both given with glargine in subjects with T1DM in a 52-week study [abstract]. Diabetes [Internet]. 2009 [cited 2014 Nov 24];58(suppl 1). Available from: http://professional.diabetes.org/Abstracts-Display.aspx?TYP=1&CID=73259
78. Garg S, McGill J, Rosenstock J, et al. Technosphere insulin vs insulin lispro in patients with type 1 diabetes using multiple daily injections [abstract]. Diabetes [Internet]. 2011 [cited 2015 Jan 12];60(suppl 1). Available from: http://professional.diabetes.org/Abstracts-Display.aspx?TYP=1&CID=87453.
79. Rosenstock J, Lorber DL, Gnudi L, et al. Prandial inhaled insulin plus basal insulin glargine versus twice daily biaspart insulin for type 2 diabetes: a multicentre randomised trial. Lancet. 2010;375:2244-2253.
80. Lee JJ, Dassau E, Zisser H, et al. In silico evaluation of an artificial pancreas combining exogenous ultrafast-acting technosphere insulin with zone model predictive control. J Diabetes Sci Technol. 2013;7:215-226.
81. William Sansum Diabetes Center; Juvenile Diabetes Research Foundation. Feasibility study using Zone-MPC controller, HMS and Technosphere® insulin inhalation system from MannnKind Corp. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US); 2000 [cited 2014 Nov 24]. Available from: http://clinicaltrials.gov/show/NCT01874392 NLM Identifier: NCT01874392.
82. Food and Drug Administration. FDA approves Afrezza to treat diabetes [Internet]. [cited 2014 Nov]. Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm403122.htm.
83. Gupta J, Felner EI, Prausnitz MR. Rapid pharmacokinetics of intradermal insulin administered using microneedles in type 1 diabetes subjects. Diabet Technol Ther. 2011;13:451-456.
84. Pettis RJ, Hirsch L, Kapitza C, et al. Microneedle-based intradermal versus subcutaneous administration of regular human insulin or insulin lispro: pharmacokinetics and postprandial glycemic excursions in patients with type 1 diabetes. Diabet Technol Ther. 2011;13:443-450.
85. Norman JJ, Brown MR, Raviele NA, et al. Faster pharmacokinetics and increased patient acceptance of intradermal insulin delivery using a single hollow microneedle in children and adolescents with type 1 diabetes. Pediatr Diabet. 2013;14:459-465.
86. Hirsch IB, Bode BW, Skyler JS, et al. Recombinant human hyaluronidase pretreatment of CSII Cannula sites provides comparable glycemic control with reduced hypoglycemia in T1DM compared to usual CSII. Diabetes [Internet]. 2014 [cited 2015 July 7];63(Suppl 1). Available from: http://ada.apprisor.org/epsSearchADA.cfm.
87. Morrow L, Muchmore DB, Ludington EA, et al. Reduction in intrasubject variability in the pharmacokinetic response to insulin after subcutaneous coadministration with recombinant human hyaluronidase in healthy volunteers. Diabet Technol Ther. 2011;13:1039-1045.
88. Hompesch M, Muchmore DB, Morrow L, et al. Accelerated insulin pharmacokinetics and improved postprandial glycemic control in patients with type 1 diabetes after coadministration of prandial insulins with hyaluronidase. Diabet Care. 2011;34:666-668.
89. Garg SK, Buse JB, Skyler JS, et al. Subcutaneous injection of hyaluronidase with recombinant human insulin compared with insulin lispro in type 1 diabetes. Diabet Obes Metab. 2014;16:1065-1069.
90. Hompesch M, Muchmore DB, Morrow L, et al. Improved postprandial glycemic control in patients with type 2 diabetes from subcutaneous injection of insulin lispro with hyaluronidase. Diabet Technol Ther. 2012;14:218-224.
91. Humulin® R regular U-500 (concentrated) insulin human injection, USP (rDNA origin) [prescribing information]. Indianapolis (IN): Eli Lilly and Company; 2014.
92. de la Pena A, Riddle M, Morrow LA, et al. Pharmacokinetics and pharmacodynamics of high-dose human regular U-500 insulin versus human regular U-100 insulin in healthy obese subjects. Diabet Care. 2011;34:2496-2501.
93. Reutrakul S, Wroblewski K, Brown RL. Clinical use of U-500 regular insulin: review and meta-analysis. J Diabetes Sci Technol. 2012;6:412-420.
94. Lane WS, Weinrib SL, Rappaport JM, et al. The effect of long-term use of U-500 insulin via continuous subcutaneous infusion on durability of glycemic control and weight in obese, insulin-resistant patients with type 2 diabetes. Endocr Pract. 2013;19:196-201.
95. Eli Lilly and Company. A study of 2 different formulations of insulin lispro in healthy participants. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US); 2000 [cited 2015 Jul 10]. Available from: https://clinicaltrials.gov/ct2/show/NCT02111083.NLM Identifier: NCT02111083.
96. Radermecker RP, Pierard GE, Scheen AJ. Lipodystrophy reactions to insulin: effects of continuous insulin infusion and new insulin analogs. Am J Clin Dermatol. 2007;8:21-28.
97. Chantelau EA, Praetor R, Praetor J, et al. Relapsing insulin-induced lipoatrophy, cured by prolonged low-dose oral prednisone: a case report. Diabetol Metab Syndr. 2011;3:33.
98. Holterhus PM, Bokelmann J, Riepe F, et al. Predicting the optimal basal insulin infusion pattern in children and adolescents on insulin pumps. Diabet Care. 2013;36:1507-1511.
99. Nicolajsen T, Samuelsson A, Hanas R. Insulin doses before and one year after pump start: children have a reversed dawn phenomenon. J Diabetes Sci Technol. 2012;6:589-594.
100. The Diabetes Research in Children Network Study Group. Impact of exercise on overnight glycemic control in children with type 1 diabetes. J Pediatr. 2005;147:528-534.
101. Sherr JL, Cengiz E, Palerm CC, et al. Reduced hypoglycemia and increased time in target using closed-loop insulin delivery during nights with or without antecedent afternoon exercise in type 1 diabetes. Diabet Care. 2013;36:2909-2914.
102. Reznik Y, Morera J, Rod A, et al. Efficacy of continuous subcutaneous insulin infusion in type 2 diabetes mellitus: a survey on a cohort of 102 patients with prolonged follow-up. Diabet Technol Ther. 2010;12:931-936.
103. Herman WH, Ilag LL, Johnson SL, et al. A clinical trial of continuous subcutaneous insulin infusion versus multiple daily injections in older adults with type 2 diabetes. Diabet Care. 2005;28:1568-1573.
104. Zeng L, Lu H, Deng H, et al. Noninferiority effects on glycemic control and beta-cell function improvement in newly diagnosed type 2 diabetes patients: basal insulin monotherapy versus continuous subcutaneous insulin infusion treatment. Diabet Technol Ther. 2012;14:35-42.
105. Reznik Y, Cohen O, Aronson R, et al. Insulin pump treatment compared with multiple daily injections for treatment of type 2 diabetes (OpT2mise): a randomised open-label controlled trial. Lancet. 2014;384:1265-1272.